Cardiac Healthcare (688016.SH) announced first-quarter results, net profit of 184 million yuan, up 47.62% year-on-year

Heart Heart Healthcare (688016.SH) disclosed its report for the first quarter of 2024. The company achieved operating revenue during the reporting period...

Zhitong FinanceApr 26 17:42

Heart Care (688016): Performance is in line with expectations, overseas revenue continues to grow rapidly

Core idea In 2023, the market coverage of the company's three core products, Castor, Minos, and Peripheral Medicine, continued to increase, and the number of innovative products Talos and Fontus admissions and terminal implants increased rapidly

中信建投證券Apr 10 19:06

Caixin Securities released a research report on April 9 stating that it gave Cardiac Healthcare (688016.SH) a purchase rating. The main reasons for the rating include: 1) achieving steady growth in aortic stents and rapid release of intraoperative stents

Caixin Securities released a research report on April 9 stating that it gave Cardiac Healthcare (688016.SH) a purchase rating. The main reasons for the rating include: 1) achieving steady growth in aortic stents and rapid release of intraoperative stents and peripheral products; 2) increasing investment in innovative research and development to actively promote the launch of various products; 3) accelerating global development and increasing overseas market coverage. (Mainichi Keizai Shimbun)

Zhitong FinanceApr 9 15:09

Cardiac Medicine (688016): Aortic Interventions Leading Peripheral Interventions, Rising Performance Growth

Incident: On March 27, 2024, Cardiac Medical released its 2023 annual report. The company achieved revenue of 1,187 billion yuan (+32.43%), net profit to mother of 492 million yuan (+37.98%), deducting net profit from non-return to mother

東北證券Apr 8 00:00

Cardiac Healthcare (688016): 2023 performance is in line with expectations, R&D is progressing smoothly

The 2023 results are in line with expectations: the company released its 2023 annual report. During the reporting period, it achieved operating income of 1,187 million yuan, an increase of 32% over the previous year; realized net profit to mother of 492 million yuan, an increase of 38% over the previous year; achieved deduction of negative funds

申萬宏源研究Apr 3 16:41

Cardiac Healthcare (688016): Steady performance, peripheral products are expected to continue to be approved

The 2023 results are in line with our expectations. The company announced 2023 results: revenue of 1.19 billion yuan, +32% year over year; net profit to mother of 490 million yuan, +38% year over year. The results were in line with our expectations. Various development trends

中金公司Mar 31 00:00